Lacosamide

From Wikipedia, the free encyclopedia

Lacosamide
Systematic (IUPAC) name
(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide
Identifiers
CAS number	175481-36-4
ATC code	N03AX18
PubChem	219078
Chemical data
Formula	C13H18N2O3
Mol. mass	250.294 g/mol
Pharmacokinetic data
Bioavailability	High
Metabolism	?
Half life	13 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral, intravenous

Lacosamide (INN, formerly known as erlosamide) is a medication developed by UCB for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain to be marketed under the trade name Vimpat.

The U.S. Food and Drug Administration has accepted UCB's New Drug Application for lacosamide as of November 29, 2007, beginning the approval process for the drug.^[1][2] UCB has also filed for marketing approval in the European Union; the European Medicines Agency accepted the marketing application for review in May 2007.^[1][3]

[edit] Clinical trials

In a large double-blind, randomized clinical trial of people with poorly controlled partial-onset seizures, lacosamide was found to significantly reduce seizure frequency when given in addition to other antiepileptics, at doses of 400 and 600 milligrams a day.^[4] In a smaller trial of people with diabetic neuropathy, lacosamide also provided significantly better pain relief when compared to placebo.^[5]

[edit] References

1. ^ ^{a b} UCB (2007-11-29). "UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain". Press release. Retrieved on 2007-11-29.
2. ^ UCB (2007-11-29). "UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy". Press release. Retrieved on 2007-11-29.
3. ^ Wan, Yuet. "Marketing application for lacosamide (Vimpat) filed in EU for treatment of diabetic neuropathic pain", PharmaTimes through the UK National electronic Library for Medicines, August 17, 2007. Retrieved on 2007-11-30. 
4. ^ Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD (2007). "Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures". Epilepsia 48 (7): 1308–17. doi:10.1111/j.1528-1167.2007.01188.x. PMID 17635557. 
5. ^ Rauck RL, Shaibani A, Biton V, Simpson J, Koch B (2007). "Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study". Clin J Pain 23 (2): 150–8. doi:10.1097/01.ajp.0000210957.39621.b2. PMID 17237664. 

v • d • e Anticonvulsants (N03) Barbiturates Barbexaclone, Metharbital, Methylphenobarbital, Pentobarbital, Phenobarbital, Primidone Hydantoins Ethotoin, Fosphenytoin, Mephenytoin, Phenytoin Oxazolidinediones Ethadione, Paramethadione, Trimethadione Succinimides Ethosuximide, Mesuximide, Phensuximide Benzodiazepines Clobazam, Clonazepam, Clorazepate, Diazepam, Lorazepam, Midazolam, Nimetazepam, Nitrazepam, Temazepam Carboxamides Carbamazepine, Oxcarbazepine, Rufinamide Fatty acid derivatives Valpromide, Valnoctamide Carboxylic acids Valproic acid (Sodium valproate & Valproate semisodium), Tiagabine Others GABA analogs: Gabapentin, Pregabalin, Progabide, Vigabatrin -- Monosaccharides: Topiramate -- Aromatic allylic alcohols: Stiripentol -- Ureas: Phenacemide, Pheneturide -- Phenyltriazines: Lamotrigine Carbamates: Emylcamate, Felbamate, Meprobamate -- Pyrrolidines: Brivaracetam, Levetiracetam, Nefiracetam, Seletracetam Sulfa drugs: Acetazolamide, Ethoxzolamide, Sultiame, Zonisamide -- Propionates: Beclamide -- Aldehydes: Paraldehyde -- Bromides: Potassium bromide, Sodium bromide